Alexza Pharmaceuticals receives marketing authorization for Adasuve in EU Alexza Pharmaceuticals announced that the European Commission has granted marketing authorization for Adasuve. In the European Union, Adasuve, 4.5 mg and 9.1 mg inhalation powder loxapine, pre-dispensed, is authorized for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The Adasuve marketing authorization requires that patients receive regular treatment immediately after control of acute agitation symptoms, and that Adasuve is administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects.
News For ALXA From The Last 14 Days
Check below for free stories on ALXA the last two weeks.